Marie Lena Hajny, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 124 Main St, Ennis, MT 59729 Phone: 406-682-4246 Fax: 406-682-7568 |
News Archive
New international guidelines published in the journal Transplantation reinforce the use of a new type of blood test to assess cytomegalovirus (CMV) risk in solid organ transplant recipients (i.e. transplant recipients). This blood test, QuantiFERON®-CMV (QF-CMV), is the first commercially-available blood test to allow physicians to monitor a person's risk of CMV disease. Most commonly used in the transplant setting, QF-CMV may predict which transplant recipients are at increased risk of CMV disease after transplant surgery.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Echo Therapeutics, Inc., a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced today that the Company has made a significant advance in the product design of its Symphony tCGM device and that it has developed its next generation electronic component package.
Insurance reform, not malpractice liability limits, held down doctors' malpractice premiums in California said Consumer Watchdog today before a Congressional hearing on H.R. 5, a bill modeled on California law that would take away the rights of patients injured by medical negligence. Limits on patient rights failed to lower physicians' malpractice premiums, and therefore health costs, in California.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase Ib expansion study for CUDC-101 in patients with advanced head and neck, gastric, breast and liver cancers.
› Verified 4 days ago